Premium
The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes
Author(s) -
Sharma Manish,
Qureshi Sofia R.,
Champlin Richard E.,
Popat Uday,
Giralt Sergio,
Qazilbash Muzaffar H.
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21740
Subject(s) - multiple myeloma , medicine , hematopoietic stem cell transplantation , immunoglobulin d , transplantation , oncology , autologous stem cell transplantation , hematology , melphalan , haematopoiesis , stem cell , gastroenterology , immunology , b cell , antibody , biology , genetics
IgD myeloma is a rare subtype of myeloma that is associated with an aggressive course, resistance to chemotherapy, and a poor outcome. We identified 17 patients with IgD myeloma, who received a hematopoietic stem cell transplantation (HCT) at our institution between August 1988 and June 2008. Fifteen of these 17 patients underwent an autologous (auto) HCT. Complete responses (CRs) were seen in 6 of 15 (40%) patients; three converted from partial response to CR, two from minimal response to CR, and one from very good partial response to CR. The overall response rate after auto HCT was 86% (13 of 15). Kaplan‐Meiers estimates of 3‐year progression‐free survival (PFS) and overall survival (OS) were 38% and 64%, respectively. Median PFS and OS were 18 and 45 months, respectively. These results were comparable with patients receiving autologous HCT for other Ig subtypes of myeloma. Am. J. Hematol. 2010. © 2010 Wiley‐Liss, Inc.